Giant Cell Arteritis (GCA)

FDA-approved biologic therapy for giant cell arteritis · Insurance & prior authorization handled

Key Takeaways

GCA is a medical emergency — vision loss can occur rapidly without treatment
Actemra (tocilizumab) is the only FDA-approved biologic for giant cell arteritis
Actemra allows significant corticosteroid tapering while maintaining GCA remission
BiologicHealthPlus handles Actemra prior authorization and delivery for GCA patients

What Is Giant Cell Arteritis?

Giant cell arteritis (GCA), also known as temporal arteritis, is a chronic inflammatory vasculitis affecting medium- and large-sized arteries — most commonly the temporal arteries and branches of the aorta. It almost exclusively affects adults over age 50 and is the most common form of systemic vasculitis in this age group.

GCA is an emergency because inflammation can rapidly occlude blood vessels supplying the optic nerve, causing permanent vision loss. Early diagnosis and treatment are critical to preventing this complication.

Symptoms of Giant Cell Arteritis

New headache, particularly at the temples
Scalp tenderness or pain when combing hair
Jaw claudication (pain in jaw muscles when chewing)
Vision changes — blurred vision, double vision, or sudden vision loss
Fatigue, fever, and unintentional weight loss
Neck or shoulder pain (polymyalgia rheumatica, which frequently co-occurs with GCA)

Biologic Treatment: Actemra for GCA

Actemra (tocilizumab), an IL-6 receptor inhibitor, is FDA-approved for giant cell arteritis in adults. The GiACTA clinical trial demonstrated that weekly subcutaneous Actemra significantly increased rates of sustained remission compared to prednisone alone, while allowing substantial corticosteroid tapering — reducing the significant long-term side effects of high-dose steroids.

💉 Dosing

Actemra for GCA: 162 mg subcutaneous injection weekly, alongside a glucocorticoid taper. Your rheumatologist will determine the specific taper schedule.

📊 Efficacy

In GiACTA trial: 56% of weekly Actemra patients achieved sustained remission vs 14% on prednisone taper alone at 52 weeks.

💰 Cost

List price ~$4,500–$5,500/month. Most commercially insured patients pay $0–$5/month with Genentech Access Solutions. BiologicHealthPlus enrolls you at no charge.

🔬 Monitoring

Regular CBC, LFTs, and lipid panel required. BiologicHealthPlus tracks your monitoring schedule and reminds you of due labs at each refill.

Most commercial insurance plans cover Actemra (tocilizumab) for GCA with prior authorization. Medicare Part B covers IV Actemra; Part D covers subcutaneous Actemra. BiologicHealthPlus verifies your specific coverage and handles all GCA prior authorization at no charge.

GCA is typically managed by a rheumatologist, often in coordination with an ophthalmologist for vision monitoring. Urgent evaluation by a rheumatologist is recommended as soon as GCA is suspected due to the risk of vision loss.

💊 BiologicHealthPlus Carries Actemra for GCA

Prior authorization, Genentech savings enrollment, and free cold-chain delivery for Actemra.

Actemra Information →

Medical Disclaimer: GCA is a medical emergency. Seek immediate medical care if you experience vision changes. Last updated: July 2026.